Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Levacetylleucine
10 evidence topics · 11 sources
Guideline recommendation: levacetylleucine for patients with neurological symptoms
“Levacetylleucine (also known as L‐acetylleucine) is a modified amino acid derivative of leucine, approved by the FDA for treating neurological manifestations of NPC in both adult and pediatric patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Statement #16: All patients with a confirmed diagnosis of NPC and neurological symptoms should be considered for levacetylleucine therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Strength of recommendation: 2” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Expert's opinion: completely agree (41.38%), mostly agree (37.93%), partially agree (17.24%), partially disagree (3.45%), mostly disagree (0.00%), and completely disagree (0.00%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Product history: first FDA approval for Niemann-Pick disease type C in 2024
| Action date | Submission | Action type | Submission classification | Review priority; orphan status |
|---|---|---|---|---|
| “09/24/2024” | “ORIG-1” | “Approval” | “Type 1 - New Molecular Entity” | “PRIORITY; Orphan” |
Regulatory status outside the United States: European Union authorisation for Niemann-Pick disease type C
| Field | Quoted record |
|---|---|
| EMA product number | “EMEA/H/C/006327” |
| Marketing authorisation holder | “Intrabio Ireland Limited” |
| Opinion adopted | “13/11/2025” |
| Marketing authorisation issued | “19/01/2026” |
Change of ownership of the manufacturer in October 2026
Molecular target: prescribing information
Phase 2 open-label, rater-blinded trial in participants aged 6 years or older
“In this multi-national, open-label, rater-blinded Phase II study, patients were assessed during a baseline period, a 6-week treatment period (orally administered NALL 4 g/day in patients ≥ 13 years, weight-tiered doses for patients 6–12 years), and a 6-week post-treatment washout period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“33 subjects aged 7–64 years with a confirmed diagnosis of NPC were enrolled.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% CI 0.25, 1.75, p = 0.029), as well as secondary endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No treatment-related serious adverse events occurred.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase 3 crossover trial: design and population in the prescribing information
SARA and fSARA treatment differences in the Niemann-Pick disease type C trial of levacetylleucine
“The primary end point was the total score on the Scale for the Assessment and Rating of Ataxia (SARA; range, 0 to 40, with lower scores indicating better neurologic status).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (±SD) change from baseline in the SARA total score was -1.97±2.43 points after 12 weeks of receiving NALL and -0.60±2.39 points after 12 weeks of receiving placebo (least-squares mean difference, -1.28 points; 95% confidence interval, -1.91 to -0.65; P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Plain language summary of the phase 3 result in a state Medicaid drug evaluation
Open-label extension at 12 and 18 months compared with a historical cohort
“Fifty-three patients aged 5–67 years (45.3% female, 54.7% male) were enrolled in the EP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean (±SD) baseline (visit 2) score on the 5-domain NPC-CSS was 11.10 (±4.73).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 12 months, the mean (±SD) change from baseline on the 5-domain NPC-CSS was −0.27 (±2.42) with NALL vs +1.5 (±3.16) in the historical cohort (95% CI −3.05 to −0.48; p = 0.009), corresponding to a 118% reduction in annual disease progression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After 18 months, the mean (±SD) change was +0.05 (±2.95) with NALL vs +2.25 (±4.74) in the historical cohort (95% CI −4.06 to −0.35; p = 0.023).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Subgroup analysis of pediatric vs adult patients demonstrated consistent benefit with NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No TEAEs occurred in more than 10% of patients on NALL, and no patients had TEAEs that were assessed by the investigator as related to NALL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote